February 13, 2020 / 2:28 PM / 14 days ago

BRIEF-Trovagene Announces Positive Data from Phase 2 Trial Of Onvansertib In Combination With Zytiga

Feb 13 (Reuters) - Trovagene Inc:

* TROVAGENE PRESENTS PHASE 2 DATA DEMONSTRATING THE ABILITY OF ONVANSERTIB TO OVERCOME ZYTIGA®-RESISTANCE AND PROVIDE CLINICAL BENEFIT FOR MCRPC PATIENTS

* TROVAGENE INC - ONVANSERTIB DEMONSTRATES EFFICACY IN ZYTIGA-RESISTANT MCRPC ACROSS KNOWN ANDROGEN RECEPTOR RESISTANCE MECHANISMS

* TROVAGENE INC - ANNOUNCED POSITIVE DATA FROM ITS ONGOING PHASE 2 TRIAL OF ONVANSERTIB IN COMBINATION WITH ZYTIGA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below